795 related articles for article (PubMed ID: 26717940)
1. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
3. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
4. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease.
Alvaro D; Bragazzi MC; Benedetti A; Fabris L; Fava G; Invernizzi P; Marzioni M; Nuzzo G; Strazzabosco M; Stroffolini T;
Dig Liver Dis; 2011 Jan; 43(1):60-5. PubMed ID: 20580332
[TBL] [Abstract][Full Text] [Related]
7. Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma?
Guglielmi A; Ruzzenente A; Campagnaro T; Pachera S; Valdegamberi A; Capelli P; Pedica F; Nicoli P; Conci S; Iacono C
J Surg Oncol; 2010 Feb; 101(2):111-5. PubMed ID: 19953578
[TBL] [Abstract][Full Text] [Related]
8. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
9. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
10. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors?
Ercolani G; Dazzi A; Giovinazzo F; Ruzzenente A; Bassi C; Guglielmi A; Scarpa A; D'Errico A; Pinna AD
Eur J Surg Oncol; 2015 Sep; 41(9):1162-9. PubMed ID: 26095704
[TBL] [Abstract][Full Text] [Related]
12. Confinement to the intrapancreatic bile duct is independently associated with a better prognosis in extrahepatic cholangiocarcinoma.
Ahn KS; Kang KJ; Kang YN; Kim YH; Kim TS
BMC Gastroenterol; 2016 Feb; 16():21. PubMed ID: 26911927
[TBL] [Abstract][Full Text] [Related]
13. Extrahepatic cholangiocarcinoma: current surgical strategy.
Boutros C; Somasundar P; Espat NJ
Surg Oncol Clin N Am; 2009 Apr; 18(2):269-88, viii. PubMed ID: 19306812
[TBL] [Abstract][Full Text] [Related]
14. The current management of hilar cholangiocarcinoma.
Jarnagin WR; Fong Y; Blumgart LH
Adv Surg; 1999; 33():345-73. PubMed ID: 10572576
[No Abstract] [Full Text] [Related]
15. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.
Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS
J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333
[TBL] [Abstract][Full Text] [Related]
16. CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma.
Nishihara Y; Aishima S; Hayashi A; Iguchi T; Fujita N; Taketomi A; Honda H; Tsuneyoshi M
Histopathology; 2009 Oct; 55(4):423-31. PubMed ID: 19817893
[TBL] [Abstract][Full Text] [Related]
17. Mass-forming intrahepatic cholangiocarcinoma presenting tumor growth in extrahepatic bile duct and superficial spreading.
Regimbeau JM; Panis Y; Nemeth J; Pocard M; de Claviere G; Soyer P; Valleur P
Hepatogastroenterology; 2003; 50(49):21-3. PubMed ID: 12629982
[TBL] [Abstract][Full Text] [Related]
18. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
19. Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.
Guglielmi A; Ruzzenente A; Campagnaro T; Valdegamberi A; Bagante F; Bertuzzo F; Conci S; Iacono C
J Gastrointest Surg; 2013 Nov; 17(11):1917-28. PubMed ID: 24048613
[TBL] [Abstract][Full Text] [Related]
20. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
